Navigation Links
SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights
Date:8/6/2009

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the Company's current plans to introduce a series of diagnostic tests, to add enhancements to the OncoCarta panel and to commercialize the AttoSense HPV test, the development of a Down syndrome test, including the conduct of clinical trials and the publication of the results of those trials, and the Company's ability to expand its genetic analysis platforms, as well as the statements under "2009 Guidance," are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with the Company's ability to develop and commercialize new technologies and products, particularly new technologies such as genetic analysis platforms, noninvasive prenatal diagnostics and laboratory developed tests, reliance upon the collaborative efforts of other parties, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals, the independent investigation and other risks detailed from time to time in the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this pres
'/>"/>

SOURCE SEQUENOM, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. SEQUENOM Announces Launch of MassARRAY Compact 96 System
2. SEQUENOM to Hold First Quarter 2009 Financial Results Conference Call on April 30
3. Webcast Alert: Sequenom: Defining the Future of Noninvasive Prenatal Diagnostics
4. Sequenom to Webcast Analyst and Investor Briefing Presentation on June 3
5. Sequenom to Webcast Analyst and Investor Briefing Presentation on September 24
6. OncoGenex Reports Second Quarter 2009 Financial Results
7. Repligen Reports First Quarter Fiscal Year 2010 Financial Results
8. PDI Reports 2009 Second Quarter Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
10. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
11. NxStage Reports Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... WORMS, GERMANY – May 26, ... GRA) announces that its manufacturing facility in Worms, ... from EXCiPACT™, an independent organization that certifies manufacturers, ... , All three Grace facilities that produce its ... gels have now received GMP certification, following the ...
(Date:5/26/2015)... and HILDEN, Germany , ... N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: ... QIAGEN Clinical Insight ® (QCI™) bioinformatics content ... interpret and report on genomic variants identified in ... for the bioinformatics platform are in oncology, for ...
(Date:5/26/2015)... -- Alere Inc. (NYSE: ALR ) (the "Company") announced today ... its Quarterly Report on Form 10-Q for the three months ... a notice from the New York Stock Exchange (the "NYSE") ... continued listing requirements under the timely filing criteria established in ... The reason for the delay relates to Company,s need ...
(Date:5/26/2015)... OHAUS Corporation, a leading manufacturer and marketer ... release a new line of Water Analysis Meters in ... a century, the OHAUS brand has been synonymous with ... Now in North America, OHAUS is demonstrating a ... water quality measurement. The OHAUS Starter Series will feature ...
Breaking Biology Technology:CORRECTION: Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 2QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 3QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 4QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 5OHAUS Corporation to Release New Water Analysis Meters in 2015 2OHAUS Corporation to Release New Water Analysis Meters in 2015 3
... ANGELES, Aug. 6 Vista Partners announced today that,it ... target on Inovio,Biomedical Corporation (Amex: INO ). "The ... DNA company that can create and deliver,therapeutic agents and ... the same valuation arena as other gene therapy,companies," said ...
... Area life science employers and candidates, SAN ... association serving the life science industry in Northern,California, ... careers,announced today the launch of an online Career ... The online employment network is accessible at, http://www.baybiocareercenter.com ...
... Mass., Aug. 6 NxStage Medical, Inc.,(Nasdaq: ... products,today announced that Jeffrey H. Burbank, Chief Executive ... in the following schedule,of investor conferences. Where possible, ... at http://www.nxstage.com/ir.cfm at the time of ...
Cached Biology Technology:Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO); $3.57 Price Target 2BayBio and BioSpace Launch Online Career Network 2NxStage Announces Investor Conference Schedule 2
(Date:5/14/2015)... 14, 2015 Research and Markets ( ... "Fingerprint Sensors Market in Smart Mobile Devices " ... that 2014 was a watershed year for fingerprint sensors ... ,Apple Pay,. Apple gave fingerprint sensors a raison d,etre ... Fingerprint sensors are a must-have feature in flagship smartphones. ...
(Date:5/11/2015)... 2015  Synaptics Incorporated (NASDAQ: SYNA ), ... announced the appointment of Wajid Ali ... reporting to Rick Bergman , President and ... Officer, Kathleen Bayless , who announced her ... Ali brings extensive financial management expertise to Synaptics, ...
(Date:5/11/2015)... May 11, 2015 Curemark LLC, a privately ... of a new Phase III double blind, randomized, placebo-controlled ... formulation, CM-AT, on all children ages 3-8 with Autism. ... Phase III double blinded clinical trial for CM-AT in ... of the digestive enzyme chymotrypsin. This new trial will ...
Breaking Biology News(10 mins):Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... fruitful collaboration between researchers at the Max Planck ... Neuchtel in Switzerland, together with contributions from colleagues ... first: the successful manipulation of a crop plant ... Genetic transformation of maize plants resulted in the ...
... (August 3, 2009) La Jolla Institute for Allergy & ... role in allergy onset, instead have discovered its previously ... important in myeloproliferative diseases and some types of lymphoma ... characterized by an overproduction of blood cells by the ...
... lung diseases like chronic bronchitis and emphysema are a ... of death and disability in developed countries, with smoking ... Work by scientists at the European Molecular Biology Laboratory ... the University of Heidelberg, Germany, has shed new light ...
Cached Biology News:Restoring a natural root signal helps to fight a major corn pest 2Restoring a natural root signal helps to fight a major corn pest 3La Jolla Institute discovers novel tumor suppressor 2La Jolla Institute discovers novel tumor suppressor 3Scientists open doors to diagnosis of emphysema 2
PAb to Hu-IFN-Alpha/Beta R2 [(IFNAR2) CD118], Rabbit Serum, neutralizing Binds to but does not neutralize human interferon alpha/beta receptor...
IMAGEQUANT 400 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
APO-BrdU™ TUNEL Assay Kit *with Alexa Fluor® 488 anti-BrdU* *60 assays*...
...
Biology Products: